Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) insider Paul Herendeen acquired 15,000 shares of the company’s stock in a transaction dated Tuesday, March 13th. The shares were purchased at an average cost of C$16.10 per share, for a total transaction of C$241,500.00.
Shares of Valeant Pharmaceuticals Intl Inc (VRX) traded down C$0.05 during midday trading on Thursday, hitting C$21.93. 1,044,022 shares of the stock were exchanged, compared to its average volume of 1,794,581. The firm has a market cap of $7,650.00, a PE ratio of 4.16 and a beta of -0.76. Valeant Pharmaceuticals Intl Inc has a twelve month low of C$11.20 and a twelve month high of C$30.56.
TRADEMARK VIOLATION NOTICE: “Valeant Pharmaceuticals Intl Inc (VRX) Insider Paul Herendeen Acquires 15,000 Shares of Stock” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another site, it was copied illegally and republished in violation of United States & international copyright laws. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/03/15/valeant-pharmaceuticals-intl-inc-vrx-insider-paul-herendeen-acquires-15000-shares-of-stock.html.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl and related companies with MarketBeat.com's FREE daily email newsletter.